Cobolimab

Modify Date: 2024-04-08 17:23:55

Cobolimab structure	Common Name	Cobolimab
	CAS Number	2022215-65-0	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Cobolimab

Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].

Name	Cobolimab

Description	Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].
Related Catalog	Research Areas >> Cancer
In Vitro	Cobolimab (0.0001-10 nM；3 d) 在预激活 T 细胞中以剂量依赖性方式促进 TIM-3 内化，IC50 值为 0.4464 nM[3]。 Cobolimab (20 µg/mL；24 h) 通过抑制 TIM-3 显著增加了 CD8+ T 细胞含量[4]。
References	[1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.

No Any Chemical & Physical Properties

Cobolimab

Use of Cobolimab

Names

Cobolimab Biological Activity

Chemical & Physical Properties